ATE401076T1 - Chinolinderivate als glucokinase liganden - Google Patents
Chinolinderivate als glucokinase ligandenInfo
- Publication number
- ATE401076T1 ATE401076T1 AT03773851T AT03773851T ATE401076T1 AT E401076 T1 ATE401076 T1 AT E401076T1 AT 03773851 T AT03773851 T AT 03773851T AT 03773851 T AT03773851 T AT 03773851T AT E401076 T1 ATE401076 T1 AT E401076T1
- Authority
- AT
- Austria
- Prior art keywords
- glucocinase
- ligands
- sup
- quinoline derivatives
- glucokinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0226931.4A GB0226931D0 (en) | 2002-11-19 | 2002-11-19 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE401076T1 true ATE401076T1 (de) | 2008-08-15 |
Family
ID=9948090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03773851T ATE401076T1 (de) | 2002-11-19 | 2003-11-13 | Chinolinderivate als glucokinase liganden |
Country Status (9)
Country | Link |
---|---|
US (1) | US7230108B2 (de) |
EP (1) | EP1583532B1 (de) |
JP (1) | JP2006514626A (de) |
AT (1) | ATE401076T1 (de) |
AU (1) | AU2003282233A1 (de) |
DE (1) | DE60322267D1 (de) |
ES (1) | ES2307992T3 (de) |
GB (1) | GB0226931D0 (de) |
WO (1) | WO2004045614A1 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
FR2864535B1 (fr) | 2003-12-24 | 2006-12-22 | Merck Sante Sas | Derives acides de quinoline et leurs applications en therapeutique |
US20080312207A1 (en) * | 2004-02-18 | 2008-12-18 | Craig Johnstone | Compounds |
DE602005013491D1 (de) * | 2004-02-18 | 2009-05-07 | Astrazeneca Ab | Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
GB0423043D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
KR20070085371A (ko) * | 2004-10-16 | 2007-08-27 | 아스트라제네카 아베 | 페녹시 벤즈아미드 화합물의 제조 방법 |
JP2008542247A (ja) * | 2005-05-24 | 2008-11-27 | アストラゼネカ アクチボラグ | グルコキナーゼモジュレーターとしての2−フェニル置換イミダゾール[4,5b]ピリジン/ピラジンおよびプリン誘導体 |
TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
JP2009500442A (ja) * | 2005-07-09 | 2009-01-08 | アストラゼネカ アクチボラグ | 2型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての2−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物 |
CA2614746C (en) * | 2005-07-09 | 2011-05-10 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
JP2009504621A (ja) * | 2005-08-09 | 2009-02-05 | アストラゼネカ アクチボラグ | 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体 |
US9202182B2 (en) * | 2005-08-11 | 2015-12-01 | International Business Machines Corporation | Method and system for analyzing business architecture |
JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
NZ566877A (en) | 2005-09-29 | 2010-05-28 | Sanofi Aventis | Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
ES2372540T3 (es) * | 2005-11-01 | 2012-01-23 | Array Biopharma, Inc. | Activadores de glucocinasa. |
TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
EP2001875A2 (de) | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase-aktivatoren |
CA2648852C (en) * | 2006-04-20 | 2012-12-11 | Pfizer Products Inc. | Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases |
JP5386350B2 (ja) | 2006-05-31 | 2014-01-15 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体 |
TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
SA07280576B1 (ar) * | 2006-10-26 | 2011-06-22 | استرازينيكا ايه بي | مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز |
US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
TW200833339A (en) | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Novel crystalline compound |
US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
CA2732165A1 (en) | 2008-08-04 | 2010-02-11 | Astrazeneca Ab | Therapeutic agents 414 |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
AR076220A1 (es) | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
WO2010116176A1 (en) * | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity |
WO2010127096A2 (en) | 2009-04-30 | 2010-11-04 | Midwestern University | Novel therapeutic treatments using centhaquin |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
US8940765B2 (en) | 2011-05-17 | 2015-01-27 | Merck Sharp & Dohme Corp. | N-linked quinolineamide M1 receptor positive allosteric modulators |
EP2880028B1 (de) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetische tricyclische verbindungen |
CA2898482A1 (en) | 2013-02-22 | 2014-08-28 | Linda L. Brockunier | Antidiabetic bicyclic compounds |
EP2970119B1 (de) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Neuartige indolderivate als antidiabetika |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2016037954A1 (de) | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung |
EP3551176A4 (de) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetische heterocyclische verbindungen |
EP3558298A4 (de) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetische spirochromanverbindungen |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
AU2018251758B2 (en) | 2017-04-10 | 2021-11-18 | Bayer Aktiengesellschaft | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1561350A (en) * | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
US5792109A (en) | 1994-09-01 | 1998-08-11 | Leland L. Ladd | Irrigation pump and system |
JPH08301760A (ja) | 1995-05-10 | 1996-11-19 | Shiseido Co Ltd | 皮膚外用剤 |
JP3168915B2 (ja) | 1995-05-25 | 2001-05-21 | 田辺製薬株式会社 | 医薬組成物 |
US6613942B1 (en) * | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | 5−アミノイソキサゾール誘導体 |
GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
KR100455635B1 (ko) * | 1999-03-29 | 2004-11-06 | 에프. 호프만-라 로슈 아게 | 글루코키나제 활성화제 |
GB9921684D0 (en) | 1999-09-15 | 1999-11-17 | Zeneca Ltd | Assays |
CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
ES2233660T3 (es) | 2000-05-03 | 2005-06-16 | F. Hoffmann-La Roche Ag | Activadores de glucokinasa alquinil fenil heteroaromaticos. |
WO2001083478A2 (en) | 2000-05-03 | 2001-11-08 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
MXPA02010796A (es) | 2000-05-08 | 2003-03-27 | Hoffmann La Roche | Fenilacetamidas sustituidas y sus usos como activadores de glucocinasa. |
EP1283830B1 (de) | 2000-05-08 | 2008-06-18 | F. Hoffmann-La Roche Ag | Para-amin substituierte phenylamid glukokinase activatoren |
PL214670B1 (pl) | 2000-06-28 | 2013-08-30 | Amgen Inc | Chinolinylowe modulatory PPAR-gamma, kompozycja je zawierajaca, zwiazek do zastosowania w leczeniu lub zapobieganiu chorobom oraz zastosowanie zwiazku do wytwarzania leku |
AU8760001A (en) | 2000-07-20 | 2002-02-05 | Hoffmann La Roche | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
WO2002024682A1 (en) * | 2000-09-25 | 2002-03-28 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors |
CA2429642C (en) * | 2000-12-06 | 2007-11-20 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
BR0212477A (pt) | 2001-09-12 | 2004-08-24 | Upjohn Co | 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças |
WO2003028641A2 (en) | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Mch receptor antagonists |
EP1336607A1 (de) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amidderivate als Glucokinase-Aktivatoren |
WO2003047626A1 (en) | 2001-12-03 | 2003-06-12 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
AU2002365611A1 (en) | 2001-12-05 | 2003-06-17 | F. Hoffmann - La Roche Ag | Inflammation modulators |
US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
EP1458382A1 (de) | 2001-12-21 | 2004-09-22 | Novo Nordisk A/S | Amidderivate als gk-aktivatoren |
AU2003221140B9 (en) | 2002-03-26 | 2009-07-30 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
CN100357283C (zh) | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | 一类甲硫氨酰氨肽酶抑制剂 |
RS93604A (en) | 2002-04-26 | 2007-02-05 | F. Hoffmann-La Roche Ag., | Substituted phenylacetamides and their use as glucokinase activators |
CA2490023A1 (en) | 2002-05-16 | 2003-11-27 | Banyu Pharmaceutical Co., Ltd. | Crystal of glucokinase protein, and method for drug design using the crystal |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
JP4390704B2 (ja) | 2002-10-03 | 2009-12-24 | エフ.ホフマン−ラ ロシュ アーゲー | グルコキナーゼ(gk)活性化物質としてのインドール−3−カルボキシアミド |
EP1549626A1 (de) | 2002-10-03 | 2005-07-06 | Novartis AG | Substituierte (thiazol-2-yl)amide oder -sulfonamide als f r die behandlung von typ-2-diabetes geeignete gylcokinaseaktivatoren |
GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
MY141521A (en) | 2002-12-12 | 2010-05-14 | Hoffmann La Roche | 5-substituted-six-membered heteroaromatic glucokinase activators |
WO2004063194A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
PT1585739E (pt) | 2003-01-06 | 2011-05-13 | Lilly Co Eli | Arilciclopropilacetamidas substitu?das como activadores da glucocinase |
US7262196B2 (en) | 2003-02-11 | 2007-08-28 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
EP1598349B1 (de) | 2003-02-13 | 2011-07-27 | Msd K.K. | Neue 2-pyridincarbonsäureamidderivate |
RU2330030C2 (ru) | 2003-02-26 | 2008-07-27 | Баниу Фармасьютикал Ко., Лтд. | Производные гетероарилкарбамоилбензола |
US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
EP1532980A1 (de) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-Heteroaryl Indol-Carboxamide und deren analoga zur Vewendung als glucokinase Aktivatoren zur Behandlung von Diabetes |
GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
GB0327760D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
GB0328178D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
WO2005063738A1 (ja) | 2003-12-29 | 2005-07-14 | Banyu Pharmaceutical Co.,Ltd | 新規2-へテロアリール置換ベンズイミダゾール誘導体 |
MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
DE602005013491D1 (de) | 2004-02-18 | 2009-05-07 | Astrazeneca Ab | Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel |
US20080312207A1 (en) | 2004-02-18 | 2008-12-18 | Craig Johnstone | Compounds |
JPWO2005090332A1 (ja) | 2004-03-23 | 2008-01-31 | 萬有製薬株式会社 | 置換キナゾリン又はピリドピリミジン誘導体 |
JP2007530631A (ja) | 2004-04-02 | 2007-11-01 | ノバルティス アクチエンゲゼルシャフト | チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法 |
ATE524479T1 (de) | 2004-04-02 | 2011-09-15 | Novartis Ag | Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren |
NZ550567A (en) | 2004-04-21 | 2010-07-30 | Prosidion Ltd | Tri(cyclo) substituted amide compounds |
TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
US20080026987A1 (en) | 2004-06-17 | 2008-01-31 | Novo Nordisk A/S | Use of Liver-Selective Glucokinase Activators |
GB0418046D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Eantioselective process |
GB0418058D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
MX2007001650A (es) | 2004-08-12 | 2007-07-13 | Prosidion Ltd | Fenilacetamidas substituidas y su uso como activadores de glucocinasa. |
GB0423043D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
GB0423044D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
KR20070085371A (ko) | 2004-10-16 | 2007-08-27 | 아스트라제네카 아베 | 페녹시 벤즈아미드 화합물의 제조 방법 |
-
2002
- 2002-11-19 GB GBGB0226931.4A patent/GB0226931D0/en not_active Ceased
-
2003
- 2003-11-13 DE DE60322267T patent/DE60322267D1/de not_active Expired - Fee Related
- 2003-11-13 AU AU2003282233A patent/AU2003282233A1/en not_active Abandoned
- 2003-11-13 JP JP2004552854A patent/JP2006514626A/ja not_active Withdrawn
- 2003-11-13 AT AT03773851T patent/ATE401076T1/de not_active IP Right Cessation
- 2003-11-13 US US10/534,651 patent/US7230108B2/en not_active Expired - Fee Related
- 2003-11-13 ES ES03773851T patent/ES2307992T3/es not_active Expired - Lifetime
- 2003-11-13 EP EP03773851A patent/EP1583532B1/de not_active Expired - Lifetime
- 2003-11-13 WO PCT/GB2003/004915 patent/WO2004045614A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP1583532B1 (de) | 2008-07-16 |
AU2003282233A1 (en) | 2004-06-15 |
US20060079553A1 (en) | 2006-04-13 |
DE60322267D1 (de) | 2008-08-28 |
JP2006514626A (ja) | 2006-05-11 |
GB0226931D0 (en) | 2002-12-24 |
US7230108B2 (en) | 2007-06-12 |
WO2004045614A1 (en) | 2004-06-03 |
EP1583532A1 (de) | 2005-10-12 |
ES2307992T3 (es) | 2008-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE401076T1 (de) | Chinolinderivate als glucokinase liganden | |
CY1115117T1 (el) | Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα | |
AU2003282234A1 (en) | Benzofuran derivates, process for their preparation and intermediates thereof | |
CY1107539T1 (el) | Παραγωγα κουιναζολινης | |
ATE264846T1 (de) | Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen | |
ATE344033T1 (de) | Vinylphenyl-derivate als glk-aktivatoren | |
MX2007000505A (es) | Derivados de oxindol sustituidos y medicamentos que contienen los mismos. | |
ATE302775T1 (de) | Carbolinderivate | |
JO2282B1 (en) | Oxazole derivatives | |
HRP20090281T1 (en) | 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases | |
DE60134874D1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
NO20044475L (no) | 2-(2,6-diklorfenyl)-diarulimidazoler | |
ECSP055809A (es) | Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 | |
ATE346067T1 (de) | Carbolinderivate | |
PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
DE60119368D1 (de) | Zusammensetzung enthaltend einen angiotensin-ii-rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck | |
MXPA05005790A (es) | Aminoalcoxiindoles como ligandos del receptor 5-ht6 para el tratamiento de enfermedades del sistema nervioso central. | |
DE60128100D1 (de) | Analgetisches arzneimittel | |
ATE259813T1 (de) | Triazolopyrimidinderivate | |
DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
MA27649A1 (fr) | Derives d'acylphenyluree substitues par carbonylamino, methode de production et d'utilisation de ceux-ci. | |
PE20030236A1 (es) | Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados | |
HUP0203161A2 (hu) | Benzamidinszármazékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |